Enanta Pharmaceuticals Inc ENTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Trading Information
- Previous Close Price
- $10.08
- Day Range
- $9.94–10.25
- 52-Week Range
- $10.07–17.15
- Bid/Ask
- $10.02 / $10.19
- Shares Outstanding
- 29.13M
- Market Cap
- $293.15M
- Volume/Avg
- 953 / 253,265
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 120
- Website
- https://www.enanta.com
Valuation
Metric | ENTA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.90 |
Price/Sales | 4.18 |
Price/Cash Flow | — |
Price/Earnings
ENTA
Financial Strength
Metric | ENTA |
|---|---|
Quick Ratio | 3.62 |
Current Ratio | 3.76 |
Interest Coverage | −4.54 |
Quick Ratio
ENTA
Profitability
Metric | ENTA |
|---|---|
Return on Assets (Normalized) | −16.80% |
Return on Equity (Normalized) | −52.39% |
Return on Invested Capital (Normalized) | −30.81% |
Return on Assets
ENTA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|T!!xhpl | LOCK|BwRf | $138B | |||
| Moderna Inc MRNA | LOCK|SNcs^ys | LOCK|xfN | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#<!!#y^ | LOCK|@<<^& | $93B | |||
| argenx SE ADR ARGX | LOCK|whlv%Q | LOCK|q%< | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|KJlMJ^ | LOCK|W& | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|hQFkGx^ | LOCK|RT%< | $30B | |||
| Incyte Corp INCY | LOCK|xZ@Rbg@ | LOCK|Mx@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|DzpcJH | LOCK|?K | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|L$%&H!^ | LOCK|MrlT> | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Zg>$@y | LOCK|%!t | $15B |
United States